resetpharma_logo.png
Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board to Deliver Keynote Presentation at The End in Mind Virtual Conference
October 14, 2021 07:30 ET | Reset Pharmaceuticals, Inc.
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board, will deliver a...
resetpharma_logo.png
UPDATE -- Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer
July 07, 2021 11:45 ET | Reset Pharmaceuticals, Inc.
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...
resetpharma_logo.png
Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer
July 07, 2021 07:00 ET | Reset Pharmaceuticals, Inc.
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...